To identify and develop a non-beta-lactam PBP inhibitor (NBP) with broad spectrum of activity against MDR gram-negative eskape pathogens.
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93020C00017
- Awardee
-
Entasis Therapeutics, Inc. UEI P6NKP5BBSUH3
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,604,274
Award facts
- Opportunity
-
- 2019 NIAID Omnibus Broad Agency Announcement Special Notice · HHSNIHNIAIDBAA20191 · Posted Jan 29, 2019
- HHS-NIH-NIAID-BAA2019-1: Research Area 002, Development of Therapeutic Products for Antibiotic Resistant Bacteria Award Notice · Posted Jun 29, 2020
- 2019 NIAID Omnibus Broad Agency Announcement Pre-Solicitation · Posted Feb 22, 2019
- Contract value 37% obligated
-
- $5,604,273.75 Current, with exercised options
- $15,259,279.75 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 12 offers Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Waltham, MA 02451, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$245,721 | |
| Funding Only Action | -$13,919 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $2,887,773 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $2,976,140 |
About this award
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $15.3 million definitive cost-no-fee contract to Entasis Therapeutics, Inc. to identify and develop a non-beta-lactam penicillin-binding protein inhibitor with broad-spectrum activity against multidrug-resistant gram-negative ESKAPE pathogens, effective July 1, 2020, with final completion on December 31, 2022.
Place of performance is Waltham, MA. The contract was cost-no-fee, with NIAID funding the research effort to address antibiotic-resistant bacterial infections identified as national health threats.
Service Contract Inventory reporting shows the contract invoiced $2.6 million in FY2021 (5.4 FTEs, 11,239 contractor hours at $227.51/hr blended rate) and $2 million in FY2022 (11.1 FTEs, 22,983 contractor hours at $84.96/hr). By FY2023, invoiced activity declined to $437 thousand (0.4 FTEs, 785 contractor hours at $556.72/hr) as the contract wound down toward its December 2022 completion date. Entasis self-performed all reported work; no subcontractors were invoiced in the final reported period.
Quick answers
Who was awarded contract 75N93020C00017?
75N93020C00017 was awarded to Entasis Therapeutics, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 1, 2020.
How much is contract 75N93020C00017 worth?
The government has obligated $5,604,274 on 75N93020C00017. Its potential value, with all options, is $15,259,280.
Was contract 75N93020C00017 competed?
The extent of competition for 75N93020C00017 was full and open competition. The government received 12 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award